1. Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement.
- Author
-
Fargnoli, Maria Concetta, Bardazzi, Federico, Bianchi, Luca, Dapavo, Paolo, Fabbrocini, Gabriella, Gisondi, Paolo, Micali, Giuseppe, Offidani, Anna Maria, Pellacani, Giovanni, Skroza, Nevena, Angileri, Rosa Giuseppa, Burlando, Martina, Campanati, Anna, Carrera, Carlo Giovanni, Chiricozzi, Andrea, Conti, Andrea, Simone, Clara De, Di Lernia, Vito, Errichetti, Enzo, and Galluzzo, Marco
- Subjects
DELPHI method ,PSORIASIS ,LIKERT scale ,MONOCLONAL antibodies - Abstract
Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against interleukin-17RA that has been approved for the treatment of moderate-to-severe psoriasis in Europe. We developed a Delphi consensus document focused on brodalumab for the treatment of moderate-to-severe psoriasis. Based on published literature and their clinical experience a steering committee drafted 17 statements covering 7 domains specific to the treatment of moderate-to-severe psoriasis with brodalumab. A panel of 32 Italian dermatologists indicated their level of agreement using a 5-point Likert scale (from 1 = "strongly disagree" to 5 = "strongly agree") using an online modified Delphi method. After the first round of voting (32 participants), positive consensus was reached for 15/17 (88.2%) of the proposed statements. Following a face-to-face virtual meeting, the steering committee decided that 5 statements would form "main principles" and 10 statements formed the final list. After a second round of voting, consensus was reached in 4/5 (80%) of the main principles and 8/10 (80%) for consensus statements. The final list of 5 main principles and 10 consensus statements identify key indications specific to the use of brodalumab in the treatment of moderate-to-severe psoriasis in Italy. These statements aid dermatologists in the management of patients with moderate-to-severe psoriasis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF